

1 **Reduced Oxygen Extraction Fraction in Deep Cerebral Veins Associated with Cognitive**
2 **Impairment in Multiple Sclerosis**

3 Hasan Sawan¹, Chenyang Li², Sagar Buch¹, Evanthia Bernitsas¹, E. Mark Haacke³, Yulin Ge²,
4 and Yongsheng Chen^{1*}

5
6 ¹Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.

7 ²Department of Radiology, New York University School of Medicine, New York, New York, USA.

8 ³Department of Radiology, Wayne State University School of Medicine, Detroit, Michigan, USA.

9

10 ***Corresponding author**

11 Yongsheng Chen, PhD.

12 Address: 4201 St. Antoine, UHC-8D, Detroit, MI 48098, USA.

13 Email: ys.chen@wayne.edu

14

15 **Acknowledgment**

16 We thank Fahad Malik for his contribution to the inter-rater reliability analysis. Research
17 reported in this publication was partially supported by the NIH/NINDS under award number
18 R61NS119434. The content is solely the responsibility of the authors and does not necessarily
19 represent the official views of the NIH. This work was also partially supported by the Office of
20 the Vice President for Research at Wayne State University through their support of the MR
21 Research Facility. The research data collection was supported by AbbVie Inc through grant
22 award number C91205.

1 **ABSTRACT**

2 Studying the relationship between cerebral oxygen utilization and cognitive impairment is
3 essential to understanding neuronal functional changes in the disease progression of multiple
4 sclerosis (MS). This study explores the potential of using venous susceptibility in internal
5 cerebral veins (ICVs) as an imaging biomarker for cognitive impairment in relapsing-remitting
6 MS (RRMS) patients. Quantitative susceptibility mapping derived from fully flow-compensated
7 MRI phase data was employed to directly measure venous blood oxygen saturation levels (S_vO_2)
8 in the ICVs. Results revealed a significant reduction in the susceptibility of ICVs (212.4 ± 30.8
9 ppb vs 239.4 ± 25.9 ppb) and a significant increase of S_vO_2 ($74.5 \pm 1.89\%$ vs $72.4 \pm 2.23\%$) in
10 patients with RRMS compared with age- and sex-matched healthy controls. Both the
11 susceptibility of ICVs ($r = 0.646, p = 0.004$) and the S_vO_2 ($r = -0.603, p = 0.008$) exhibited a
12 strong correlation with cognitive decline in these patients assessed by the Paced Auditory Serial
13 Addition Test, while no significant correlation was observed with clinical disability measured by
14 the Expanded Disability Status Scale. The findings suggest that venous susceptibility in ICVs has
15 the potential to serve as a specific indicator of oxygen metabolism and cognitive function in
16 RRMS.

1 INTRODUCTION

2 Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease characterized by
3 neural tissue atrophy and multifocal inflammatory and demyelinating lesions in the central
4 nervous system.¹ The cause and course of MS lesions are not fully elucidated, with
5 neurodegeneration emerging as the primary driving force behind both disease progression and
6 cognitive decline.² Several hypotheses underlie progressive neurodegeneration in MS. One
7 explanation revolves around energy deficiency in lesions, termed virtual (also known as
8 metabolic or histotoxic) hypoxia.³ In contrast to “true” hypoxia, virtual hypoxia does not
9 necessarily involve reduced oxygen availability; rather, it is characterized by diminished oxygen
10 utilization with mitochondrial dysfunction. Virtual hypoxia likely plays a significant role in the
11 pathophysiology of neurodegeneration in MS.⁴ This effect is not just localized to lesions;
12 reduced oxygen extraction fraction (OEF), a marker of cell degeneration or dysfunction, has
13 been described in normal-appearing tissue, including in deep and cortical gray matter of MS
14 patients.^{5,6}

15 Furthermore, a reduced cerebral metabolic rate of oxygen (CMRO₂), a similar measure of
16 OEF, has long been related to symptomatology of MS, particularly cognitive impairment.⁶⁻⁹
17 Cognitive impairment in MS can arise from decreased oxygen metabolism manifesting either as
18 direct damage to brain tissue or as a decline in neuronal/axonal activity.¹⁰⁻¹² Specifically,
19 cognitive dysfunction is linked to damage in deep gray matter nuclei^{11, 13, 14}, with the thalamus
20 being identified as the primary contributor.^{15, 16} Therefore, measurements of OEF in deep
21 cerebral regions could serve as a specific imaging biomarker of cognitive decline in MS.

22 Studies on cerebral oxygen metabolism have traditionally relied on positron emission
23 tomography (PET), the gold-standard, for assessment of CMRO₂ in MS.^{7, 9, 17} However, PET is

1 disadvantaged clinically by exposure to radiation and relatively limited availability. Recently,
2 non-invasive MRI-based methods have emerged as a major focus for the quantification of OEF
3 and CMRO₂.¹⁸⁻²⁰ Various techniques measuring cerebral OEF have been proposed, including
4 phase or quantitative susceptibility mapping (QSM) based methods²¹⁻²³ and a T2-relaxation-
5 under-spin-tagging (TRUST) method²⁴ for measuring macrovascular OEF; respiratory challenge
6 calibrated blood-oxygen-level-dependent (BOLD) methods²⁵⁻²⁷; calibration-free quantitative
7 BOLD based methods²⁸⁻³⁰; QSM-based voxel-wise OEF mappings³¹⁻³³; as well as methods
8 combining quantitative BOLD and QSM³⁴⁻³⁶. *Ge et al.* observed a significantly decreased OEF in
9 MS patients measured in the superior sagittal sinus (SSS) using the TRUST method.⁸ The
10 reduction of OEF was correlated with disease severity and total lesion load.⁸ *Fan et al.* also
11 reported a reduction of cortical OEF in MS, using a phase-based method measuring pial veins
12 parallel to the main field.⁶ More recently, *Cho et al.* utilized a voxel-wise OEF method
13 combining QSM and quantitative BOLD, observing a whole brain region reduced OEF in MS
14 patients.⁵ Common among these various methods is the use of venous blood susceptibility as a
15 direct measure of venous oxygen saturation levels (S_vO_2) and OEF of the veins draining the
16 cerebral tissue. QSM also eliminates the orientation-based errors in phase-based methods, which
17 can accurately measure susceptibility predominantly for veins parallel to the main field.³⁷ To its
18 advantage, the venous QSM-based OEF method is readily available in clinical settings with
19 minimal requirement for image post-processing.^{37, 38} However, it remains largely unknown
20 whether the susceptibility of cerebral veins can be used as an imaging biomarker of neuronal
21 activity in MS. Deep cerebral veins such as internal cerebral veins (ICVs) drain the
22 periventricular white matter (WM) where most MS lesions including the slowly expanding

1 lesions occur³⁹, as well as subcortical grey matter nuclei which are associated with cognitive
2 function¹¹.

3 The objective of this study was to investigate the susceptibility of ICVs and the
4 subsequent S_vO₂ in patients with relapsing-remitting MS (RRMS), and their underlying
5 correlations with a clinical measure of cognitive function and disease severity.

6 **METHODS**

7 **Subjects and Clinical Assessments**

8 Patients with RRMS and age-matched healthy controls (HC) were recruited from the Neurology
9 clinic at Wayne State University and approved by the local institutional review board. Written
10 consent was obtained from each participant. The inclusion and exclusion criteria were described
11 in a previous publication using the quantitative MRI data acquired from the same cohorts.⁴⁰ A
12 neurologist performed clinical assessment for MS patients, including the Expanded Disability
13 Status Scale (EDSS) for disease severity⁴¹ and the Paced Auditory Serial Addition Test (PASAT)
14 for cognitive function.⁴²

15 **Data Acquisition and Processing**

16 The QSM data presented in this paper were acquired with an interleaved flow-rephased and
17 flow-dephased gradient echo sequence⁴³. The data used in this retrospective study was not
18 published previously. The imaging parameters were as follows: TR = 20 ms, flip angle = 12°,
19 two echoes of 12.5 ms acquired with interleaved TRs, and an acquisition resolution of 0.67 x
20 1.34 x 2.0 mm³. There were 80 axial slices covering the whole brain. The scan time was 4 min
21 53 sec. The interleaved sequence had a fully flow-compensated echo of 12.5 ms for a bright
22 blood image, and a flow-dephased echo of 12.5 ms for a dark blood image (Fig. 1A and 1B). The

1 subtraction of these two magnitude images yielded an MR angiogram and venogram (MRAV)
2 with no background tissue remaining (Fig. 1C)⁴³. The phase of the flow-compensated echo was
3 used for the reconstruction of the QSM data as described (Fig. 1D)⁴³. In short, a quality-guided
4 3D best path algorithm, 3DSRNCP⁴⁴, was used for phase unwrapping followed by background
5 field removal using the SHARP algorithm with a kernel size of 8 pixels and a deconvolution
6 threshold of 0.05⁴⁵. Then, a truncated k-space division (TKD) was used to solve the inverse
7 problem and to generate an initial susceptibility map²¹. Finally, an iterative algorithm with 4
8 iterations and a threshold-based geometry mask indicating major veins and high-susceptibility
9 deep grey matter nuclei was used to reduce the streaking artifacts on the TKD-generated QSM.⁴⁶
10 The final iterated QSM data improves the accuracy of the susceptibility for major veins, such as
11 the ICVs.⁴⁶

12 **Data Analysis**

13 Two observers independently traced the ICVs using a semi-automated region-growing tool in
14 SPIN software (V1.5, MR Innovations Inc, Detroit, MI) on a maximum intensity projection (MIP)
15 over 8 slices of the QSM data (Fig. 1D). To investigate the inter-rater and intra-rater reliability,
16 each observer delineated the region-of-interest (ROI) of the ICVs again on all data a week after
17 the initial delineation. To minimize the partial volume effect (PVE), the ROI was placed at the
18 middle segment of the ICVs between the thalamostriate veins and medial atrial veins (Fig. 1D).
19 Patient disease status was blinded to the observers during ROI delineation. The median
20 susceptibility value of all pixels within the ROI ($\Delta\chi_{ICV}$) was used for each subject. Subsequently,
21 the χ_{ICV} was converted to S_vO_2 using Eq 1.

$$22 \quad S_vO_{2(ICV)} = 1 - (\Delta\chi_{ICV} - \Delta\chi_{oxy} \cdot Hct) / (\Delta\chi_{do} \cdot Hct) \quad (\text{Eq. 1})$$

1 where $\Delta\chi_{ICV}$ is the measured susceptibility of the ICVs relative to water, $\Delta\chi_{oxy}$ is the
2 susceptibility difference between fully oxygenated blood and water ($-0.03 \times 4\pi$ ppm), $\Delta\chi_{do}$ is the
3 susceptibility difference between fully oxygenated and deoxygenated blood ($0.27 \times 4\pi$ ppm), and
4 Hct is the average hematocrit expected for women (0.43) and men (0.45).^{47, 48}

5 Statistical analysis was performed using MATLAB (R2017b, MathWorks, Natick, MA)
6 with in-house developed scripts. The Wilcoxon rank sum test was used to compare the age,
7 gender percentage, $\Delta\chi_{ICV}$, and S_vO_2 between the two cohorts. Inter-rater reliability of $\Delta\chi_{ICV}$ was
8 assessed by the intraclass correlation coefficient (ICC) analysis⁴⁹ and linear regression. Linear
9 regression was used to correlate $\Delta\chi_{ICV}$ with PASAT and EDSS scores in MS patients. $P < 0.05$
10 was considered statistically significant.

11 RESULTS

12 The study enrolled 20 patients with RRMS and 10 age-matched HCs. Two MS patients' data
13 were excluded from the present study due to strong susceptibility artifacts caused by calcification
14 in the pineal gland (around which the ICVs bifurcate from the great cerebral vein). The
15 demographics and clinical assessments are listed in Table 1. The age and gender percentage were
16 comparable between MS and HC. The reliability analysis demonstrated an excellent intra-rater
17 (ICC = 0.97, $r^2 = 0.97$, $p < 0.001$) and inter-rater (ICC = 0.96, $r^2 = 0.97$, $p < 0.001$) agreement of
18 the measuring method. Compared with HCs, patients with MS had a significantly reduced $\Delta\chi_{ICV}$
19 (212.4 ± 30.8 ppb in MS vs 239.4 ± 25.9 ppb in HC), and a significantly increased S_vO_2 ($74.5 \pm$
20 1.89 % in MS vs 72.4 ± 2.23 % in HC), as shown in Fig. 2A and 2B. The PASAT score, a
21 measure of cognitive function, was strongly correlated with the $\Delta\chi_{ICV}$ ($r = 0.646$, $p = 0.004$) and
22 the S_vO_2 ($r = -0.603$, $p = 0.008$) in MS patients (Fig. 2C and 2D). In contrast, the disease severity

1 score, EDSS, had no correlation effect with $\Delta\chi_{ICV}$ ($r = -0.295$, $p = 0.236$), nor S_vO_2 ($r = 0.279$, p
2 $= 0.260$) in MS patients.

3 **DISCUSSION**

4 In this study, we observed a reduced susceptibility of ICVs in RRMS patients compared to age-
5 and sex-matched controls, indicating decreased deoxyhemoglobin levels in venous blood in
6 ICVs. Consequently, there was an increased S_vO_2 in these patients, implicating a decreased OEF
7 in the corresponding cerebral regions draining into the ICVs. These imaging biomarkers were
8 correlated with cognitive impairment in these MS patients, as measured by PASAT. The high
9 intra- and inter-rater ICC scores affirm the repeatability and reproducibility of the method.

10 Oxygen molecules bind to hemoglobin by eliminating unpaired electrons, forming
11 diamagnetic oxyhemoglobin. Upon the release of oxygen from oxyhemoglobin in neuronal
12 tissue, deoxyhemoglobin in venous blood becomes paramagnetic, resulting in relatively strong
13 magnetic field perturbations in MRI. Therefore, the susceptibility of venous blood can serve as a
14 direct measure of S_vO_2 given the negligible effect of other sources of susceptibility changes in
15 the blood⁴⁸. The phase accumulation as measured for a given echo time in a gradient echo
16 sequence is proportional to the susceptibility changes. Indeed, phase images have been used to
17 directly measure the S_vO_2 of pial veins parallel to the main field, where there is no magnetic
18 dipole inversion.^{6, 21, 22} In this regard, QSM reconstructed from phase data makes it possible to
19 measure venous blood oxygenation in all orientations^{21, 37, 38}. However, the typically used multi-
20 echo fitting based QSM often acquires the gradient echo data with a very short first TE and small
21 echo spacing, making it impractical to use flow compensation in all gradient directions.^{37, 50}
22 Uncompensated blood flow thereby becomes the major source of error in venous-QSM based
23 OEF measurement.²³ In addition, gradient echo sequences in clinical MRI scanners only have

1 flow compensation options for the first echo, but not for the second and subsequent echoes. To
2 overcome these issues, we used a single-echo based QSM method along with flow compensation
3 in all gradient directions to minimize blood flow induced phase errors.^{43, 46} Furthermore, we used
4 an optimal echo time of 12.5 ms, which is a fat-water in-phase echo time close to $T_2^*/2$ of the
5 venous blood, to give sufficient signal-to-noise ratio (SNR) of the venous blood phase while also
6 avoiding intravoxel aliasing of the data coming from the edges of veins.³⁷ Although the present
7 study used the QSM data acquired from a customized interleaved MRAV sequence, an identical
8 equivalent can be implemented on clinical scanners using the product gradient echo sequence
9 with a scan time of 2 min 27 sec by eliminating the interleaved TR for the subtraction-based
10 MRAV.⁴³

11 The observed increased S_vO_2 in the ICVs is likely due to reduced oxygen consumption in
12 the deep cerebral regions that drain into the ICV, which include periventricular WM and deep
13 gray matter regions. The superior thalamostriate veins, which drain the corpus striatum and
14 thalamus, unite with the superior choroid veins, which drain the hippocampus, fornix, and corpus
15 callosum, to become the ICVs.⁵¹ Damage to any of these deep gray matter nuclei are implicated
16 in cognitive impairment in MS.^{11, 13-16} The association found in this study between increased
17 S_vO_2 and cognitive impairment suggests that reduced oxygen consumption, possibly due to
18 virtual hypoxia, is a factor in the damage to these regions. This further aligns with previous
19 studies that found reduced $CMRO_2$ in deep gray matter nuclei.^{5, 6} In addition, reduced oxygen
20 consumption in deep cerebral gray matter may play a key role in cognitive function in other
21 neurodegenerative disorders such as Alzheimer's disease.⁵² WM damage is also of note, as the
22 subependymal veins, which drain the periventricular WM regions through medullary veins, in
23 turn drain into the ICVs. The periventricular region where MS lesions are most commonly seen

1 may also play a role in explaining S_vO_2 increases in the ICVs. Previous studies have explored the
2 role of WM and reported a contribution from WM to MS-related cognitive impairment.^{53, 54} This
3 is also in line with a previous study demonstrating diminished medullary vein visibility in
4 periventricular WM territories in MS patients.⁵⁵ Taken together, the findings of this study
5 emphasize the utility of deep cerebral venous susceptibility as a potential imaging biomarker of
6 cognitive decline in RRMS as well as normal aging and other neurodegenerative disorders.

7 There are several limitations to this study. First, this retrospective study includes only a
8 small cohort of RRMS patients. While RRMS patients constitute most MS patients⁵⁶, limiting the
9 cohort to a single MS subtype may miss an opportunity to explore varying profiles of pathology,
10 given that the prevalence of cognitive impairment varies widely among subtypes.⁵⁷ Second,
11 while χ_{ICV} and S_vO_2 are good measures of venous deoxyhemoglobin and oxygenation, they fall
12 short of being a complete stand-in for OEF as understood by Fick's principle, which also
13 requires a measurement of arterial blood oxygen saturation supplying the same tissue. Although
14 arterial oxygen saturation levels can be measured by a finger pulse oximeter⁸, this data was not
15 collected from the present cohort when they underwent MRI. Importantly, true hypoxia plays an
16 equally prevalent role in MS⁴, and previous studies have found lowered deep gray matter blood
17 oxygen saturation in MS using infrared spectroscopy — reasonably, oxygen saturation in the
18 finger may vary from that in the cerebrum.⁵⁸ Further studies would benefit from measuring
19 arterial blood oxygen saturation, ideally in the counterpart arteries to the ICVs. Third, QSM
20 reconstruction has a step of brain extraction which typically discards cerebral edge regions
21 including most of the cortical veins and the SSS.³⁷ Thus, the current method is limited to
22 measuring only from veins available in the QSM data. This could be circumvented in future
23 studies by using whole brain QSM methods.^{59, 60} Fourth, PASAT alone may not be the most

1 reliable indicator of our participants' cognitive function. Despite its high test-retest reliability
2 and internal consistency, it is influenced by patients' mathematical abilities, intelligence
3 quotient, and age.⁴² Finally, significant PVE of the ICVs was observed by the generally lower
4 venous susceptibility compared to the theoretical value of 450 ppb.³⁷ The PVE could be reduced
5 by using a higher imaging resolution. Practically speaking, acquiring a single echo with full flow
6 compensation and a resolution of $0.5 \times 0.5 \times 1.5 \text{ mm}^3$ could be achieved in less than 5 minutes
7 on clinical MRI scanners. This could be accomplished by using a TE of 12.5 ms, a TR of 20 ms,
8 a low bandwidth of 150 Hz/pixel to ensure the SNR of the data, a parallel imaging acceleration
9 factor of 2, and 80 axial slices covering most of the brain. Further studies should consider the
10 correction of PVE in QSM reconstruction. Nevertheless, the findings of this study are endorsed
11 by the excellent agreement of the inter-rater and intra-rater analyses, and the factor that the exact
12 same method was used on patients and controls.

13 In summary, this study demonstrates the feasibility of using deep cerebral venous
14 susceptibility as an imaging biomarker of cognitive impairment in MS. This pilot study warrants
15 further investigation of cerebral venous QSM as a clinically feasible tool in assessing cerebral
16 oxygen metabolism in large-scale prospective clinical studies in MS and other neurodegenerative
17 disorders.

1 **Figures and Tables**

2 **Figure 1.** Representative images and regions-of-interest (ROI) for the internal cerebral veins
3 (ICVs). The sequence provides a fully flow-compensated bright blood image (A) and a flow-
4 dephased dark blood image (B). The subtraction of the two magnitude images gives MRAV data
5 (C). The phase of the flow-compensated echo was used for reconstructing the QSM data (D).
6 The ROI of the ICVs is shown as the red boundary in the inset (D).

7
8 **Figure 2.** Increased deep cerebral venous blood oxygenation was correlated with cognitive
9 decline. The box plot analysis shows a reduced $\Delta\chi_{ICV}$ (A) and increased S_vO_2 (C) in MS
10 compared with healthy controls (HC). The PASAT score was correlated with $\Delta\chi_{ICV}$ (C) and S_vO_2
11 (D) in MS patients. One outlier with the lowest PASAT score (red data points on C and D) was
12 excluded during the correlation analyses.

13
14 **Table 1.** Demographics and data. Data were presented as mean \pm standard deviation (minimum–
15 maximum).

	MS Patients (n = 18)	Controls (n = 10)	<i>p</i> -value
Age (years)	36.7 \pm 7.7 (24 – 54)	35.6 \pm 12.7 (21 – 58)	0.262
Male Percentage (%)	27.8	40.0	0.534
χ_{ICV} (ppb)	212.4 \pm 30.8 (161.0 – 267.0)	239.4 \pm 25.9 (178.5 – 263.8)	0.026*
S_vO_2 (%)	74.5 \pm 1.89 (71.4 – 78.3)	72.4 \pm 2.23 (69.9 – 77.2)	0.023*
PASAT	38.8 \pm 14.3 (15.0 – 60.0)	-	-
EDSS	5.7 \pm 4.2 (1.0 – 17.0)	-	-

16

1 REFERENCES

- 2 1. Grigoriadis N and Van Pesch V. A basic overview of multiple sclerosis immunopathology.
3 *European journal of neurology*. 2015; 22: 3-13.
- 4 2. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M and Lassmann H.
5 Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
6 *Annals of Neurology: Official Journal of the American Neurological Association and the Child*
7 *Neurology Society*. 2000; 47: 707-17.
- 8 3. Trapp BD and Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in
9 multiple sclerosis. *The Lancet Neurology*. 2009; 8: 280-91.
- 10 4. Halder SK and Milner R. Hypoxia in multiple sclerosis; is it the chicken or the egg?
11 *Brain*. 2021; 144: 402-10.
- 12 5. Cho J, Nguyen TD, Huang W, et al. Brain oxygen extraction fraction mapping in patients
13 with multiple sclerosis. *Journal of Cerebral Blood Flow & Metabolism*. 2022; 42: 338-48.
- 14 6. Fan AP, Govindarajan ST, Kinkel RP, et al. Quantitative oxygen extraction fraction from
15 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. *Journal of Cerebral*
16 *Blood Flow & Metabolism*. 2015; 35: 131-9.
- 17 7. Brooks D, Leenders K, Head G, Marshall J, Legg N and Jones T. Studies on regional
18 cerebral oxygen utilisation and cognitive function in multiple sclerosis. *Journal of neurology,*
19 *neurosurgery, and psychiatry*. 1984; 47: 1182.
- 20 8. Ge Y, Zhang Z, Lu H, et al. Characterizing brain oxygen metabolism in patients with
21 multiple sclerosis with T2-relaxation-under-spin-tagging MRI. *Journal of Cerebral Blood Flow*
22 *& Metabolism*. 2012; 32: 403-12.

- 1 9. Sun X, Tanaka M, Kondo S, Okamoto K and Hirai S. Clinical significance of reduced
2 cerebral metabolism in multiple sclerosis: a combined PET and MRI study. *Annals of nuclear*
3 *medicine*. 1998; 12: 89-94.
- 4 10. Margoni M, Preziosa P, Rocca MA and Filippi M. Depressive symptoms, anxiety and
5 cognitive impairment: emerging evidence in multiple sclerosis. *Translational Psychiatry*. 2023;
6 13: 264.
- 7 11. Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive
8 dysfunction in multiple sclerosis. *The Lancet Neurology*. 2015; 14: 302-17.
- 9 12. Tozlu C, Olafson E, Jamison KW, et al. The sequence of regional structural
10 disconnectivity due to multiple sclerosis lesions. *Brain Communications*. 2023; 5: fcad332.
- 11 13. Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy
12 predicting slowed cognitive processing in multiple sclerosis. *Journal of neurology*. 2012; 259:
13 139-46.
- 14 14. Muhlert N, Atzori M, De Vita E, et al. Memory in multiple sclerosis is linked to
15 glutamate concentration in grey matter regions. *Journal of Neurology, Neurosurgery &*
16 *Psychiatry*. 2014.
- 17 15. Houtchens M, Benedict R, Killiany R, et al. Thalamic atrophy and cognition in multiple
18 sclerosis. *Neurology*. 2007; 69: 1213-23.
- 19 16. Minagar A, Barnett MH, Benedict RH, et al. The thalamus and multiple sclerosis: modern
20 views on pathologic, imaging, and clinical aspects. *Neurology*. 2013; 80: 210-9.
- 21 17. Brier MR and Taha F. Measuring Pathology in Patients with Multiple Sclerosis Using
22 Positron Emission Tomography. *Current neurology and neuroscience reports*. 2023; 23: 479-88.

- 1 18. Biondetti E, Cho J and Lee H. Cerebral oxygen metabolism from MRI susceptibility.
2 *NeuroImage*. 2023; 276: 120189.
- 3 19. Jiang D and Lu H. Cerebral oxygen extraction fraction MRI: Techniques and
4 applications. *Magnetic resonance in medicine*. 2022; 88: 575-600.
- 5 20. Rodgers ZB, Detre JA and Wehrli FW. MRI-based methods for quantification of the
6 cerebral metabolic rate of oxygen. *Journal of Cerebral Blood Flow & Metabolism*. 2016; 36:
7 1165-85.
- 8 21. Haacke E, Tang J, Neelavalli J and Cheng Y. Susceptibility mapping as a means to
9 visualize veins and quantify oxygen saturation. *Journal of Magnetic Resonance Imaging*. 2010;
10 32: 663-76.
- 11 22. Fan AP, Bilgic B, Gagnon L, et al. Quantitative oxygenation venography from MRI
12 phase. *Magnetic resonance in medicine*. 2014; 72: 149-59.
- 13 23. Xu B, Liu T, Spincemaille P, Prince M and Wang Y. Flow compensated quantitative
14 susceptibility mapping for venous oxygenation imaging. *Magnetic resonance in medicine*. 2014;
15 72: 438-45.
- 16 24. Lu H and Ge Y. Quantitative evaluation of oxygenation in venous vessels using T2-
17 relaxation-under-spin-tagging MRI. *Magnetic Resonance in Medicine: An Official Journal of the*
18 *International Society for Magnetic Resonance in Medicine*. 2008; 60: 357-63.
- 19 25. Bulte DP, Kelly M, Germuska M, et al. Quantitative measurement of cerebral physiology
20 using respiratory-calibrated MRI. *Neuroimage*. 2012; 60: 582-91.
- 21 26. Gauthier CJ and Hoge RD. A generalized procedure for calibrated MRI incorporating
22 hyperoxia and hypercapnia. *Human brain mapping*. 2013; 34: 1053-69.

- 1 27. Wise RG, Harris AD, Stone AJ and Murphy K. Measurement of OEF and absolute
2 CMRO₂: MRI-based methods using interleaved and combined hypercapnia and hyperoxia.
3 *Neuroimage*. 2013; 83: 135-47.
- 4 28. Yablonskiy DA and Haacke EM. Theory of NMR signal behavior in magnetically
5 inhomogeneous tissues: the static dephasing regime. *Magnetic resonance in medicine*. 1994; 32:
6 749-63.
- 7 29. He X and Yablonskiy DA. Quantitative BOLD: mapping of human cerebral
8 deoxygenated blood volume and oxygen extraction fraction: default state. *Magnetic Resonance*
9 *in Medicine: An Official Journal of the International Society for Magnetic Resonance in*
10 *Medicine*. 2007; 57: 115-26.
- 11 30. An H and Lin W. Quantitative measurements of cerebral blood oxygen saturation using
12 magnetic resonance imaging. *Journal of Cerebral Blood Flow & Metabolism*. 2000; 20: 1225-36.
- 13 31. Zhang J, Cho J, Zhou D, et al. Quantitative susceptibility mapping-based cerebral
14 metabolic rate of oxygen mapping with minimum local variance. *Magnetic Resonance in*
15 *Medicine*. 2018; 79: 172-9.
- 16 32. Zhang J, Liu T, Gupta A, Spincemaille P, Nguyen TD and Wang Y. Quantitative mapping
17 of cerebral metabolic rate of oxygen (CMRO₂) using quantitative susceptibility mapping (QSM).
18 *Magnetic resonance in medicine*. 2015; 74: 945-52.
- 19 33. Zhang J, Zhou D, Nguyen TD, Spincemaille P, Gupta A and Wang Y. Cerebral metabolic
20 rate of oxygen (CMRO₂) mapping with hyperventilation challenge using quantitative
21 susceptibility mapping (QSM). *Magnetic resonance in medicine*. 2017; 77: 1762-73.
- 22 34. Cho J, Kee Y, Spincemaille P, et al. Cerebral metabolic rate of oxygen (CMRO₂)
23 mapping by combining quantitative susceptibility mapping (QSM) and quantitative blood




- 1 oxygenation level-dependent imaging (qBOLD). *Magnetic resonance in medicine*. 2018; 80:
2 1595-604.
- 3 35. Cho J, Lee J, An H, Goyal MS, Su Y and Wang Y. Cerebral oxygen extraction fraction
4 (OEF): Comparison of challenge-free gradient echo QSM+ qBOLD (QQ) with 15O PET in
5 healthy adults. *Journal of Cerebral Blood Flow & Metabolism*. 2021; 41: 1658-68.
- 6 36. Cho J, Ma Y, Spincemaille P, Pike GB and Wang Y. Cerebral oxygen extraction fraction:
7 comparison of dual-gas challenge calibrated BOLD with CBF and challenge-free gradient echo
8 QSM+ qBOLD. *Magnetic resonance in medicine*. 2021; 85: 953-61.
- 9 37. Haacke EM, Liu S, Buch S, Zheng W, Wu D and Ye Y. Quantitative susceptibility
10 mapping: current status and future directions. *Magnetic resonance imaging*. 2015; 33: 1-25.
- 11 38. Buch S, Ye Y and Haacke EM. Quantifying the changes in oxygen extraction fraction and
12 cerebral activity caused by caffeine and acetazolamide. *Journal of Cerebral Blood Flow &
13 Metabolism*. 2017; 37: 825-36.
- 14 39. Buch S, Subramanian K, Chen T, et al. Characterization of white matter lesions in
15 multiple sclerosis using proton density and T1-relaxation measures. *Magnetic Resonance
16 Imaging*. 2023.
- 17 40. Haacke EM, Bernitsas E, Subramanian K, et al. A Comparison of Magnetic Resonance
18 Imaging Methods to Assess Multiple Sclerosis Lesions: Implications for Patient Characterization
19 and Clinical Trial Design. *Diagnostics*. 2021; 12: 77.
- 20 41. Meyer-Moock S, Feng Y-S, Maeurer M, Dippel F-W and Kohlmann T. Systematic
21 literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the

- 1 Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. *BMC*
- 2 *neurology*. 2014; 14: 1-10.
- 3 42. Tombaugh TN. A comprehensive review of the paced auditory serial addition test
- 4 (PASAT). *Archives of clinical neuropsychology*. 2006; 21: 53-76.
- 5 43. Chen Y, Liu S, Buch S, Hu J, Kang Y and Haacke EM. An interleaved sequence for
- 6 simultaneous magnetic resonance angiography (MRA), susceptibility weighted imaging (SWI)
- 7 and quantitative susceptibility mapping (QSM). *Magnetic resonance imaging*. 2018; 47: 1-6.
- 8 44. Abdul-Rahman HS, Gdeisat MA, Burton DR, Lalor MJ, Lilley F and Moore CJ. Fast and
- 9 robust three-dimensional best path phase unwrapping algorithm. *Applied optics*. 2007; 46: 6623-
- 10 35.
- 11 45. Schweser F, Deistung A, Lehr BW and Reichenbach JR. Quantitative imaging of intrinsic
- 12 magnetic tissue properties using MRI signal phase: an approach to in vivo brain iron
- 13 metabolism? *Neuroimage*. 2011; 54: 2789-807.
- 14 46. Tang J, Liu S, Neelavalli J, Cheng YC, Buch S and Haacke EM. Improving susceptibility
- 15 mapping using a threshold-based K-space/image domain iterative reconstruction approach. *Magn*
- 16 *Reson Med*. 2013; 69: 1396-407.
- 17 47. Spees WM, Yablonskiy DA, Oswood MC and Ackerman JJ. Water proton MR properties
- 18 of human blood at 1.5 Tesla: Magnetic susceptibility, T1, T2, T, and non-Lorentzian signal
- 19 behavior. *Magnetic Resonance in Medicine: An Official Journal of the International Society for*
- 20 *Magnetic Resonance in Medicine*. 2001; 45: 533-42.

- 1 48. Weisskoff RM and Kiihne S. MRI susceptometry: image-based measurement of absolute
2 susceptibility of MR contrast agents and human blood. *Magnetic resonance in medicine*. 1992;
3 24: 375-83.
- 4 49. Shrout PE and Fleiss JL. Intraclass correlations: uses in assessing rater reliability.
5 *Psychological bulletin*. 1979; 86: 420.
- 6 50. Wang Y and Liu T. Quantitative susceptibility mapping (QSM): decoding MRI data for a
7 tissue magnetic biomarker. *Magnetic resonance in medicine*. 2015; 73: 82-101.
- 8 51. Wang J, Wang J, Sun J and Gong X. Evaluation of the anatomy and variants of internal
9 cerebral veins with phase-sensitive MR imaging. *Surgical and radiologic anatomy*. 2010; 32:
10 669-74.
- 11 52. Yang A, Zhuang H, Du L, et al. Evaluation of whole-brain oxygen metabolism in
12 Alzheimer's disease using QSM and quantitative BOLD. *NeuroImage*. 2023; 282: 120381.
- 13 53. Elkhooly M, Bao F, Raghieb M, Millis S and Bernitsas E. Role of white matter in
14 cognitive impairment among relapsing remitting multiple sclerosis patients. *Multiple Sclerosis*
15 *and Related Disorders*. 2023; 79: 105030.
- 16 54. Engl C, Tiemann L, Grahl S, et al. Cognitive impairment in early MS: contribution of
17 white matter lesions, deep grey matter atrophy, and cortical atrophy. *Journal of Neurology*. 2020;
18 267: 2307-18.
- 19 55. Ge Y, Zohrabian VM, Osa EO, et al. Diminished visibility of cerebral venous vasculature
20 in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. *Journal of Magnetic*
21 *Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in*
22 *Medicine*. 2009; 29: 1190-4.

- 1 56. Klineova S and Lublin FD. Clinical course of multiple sclerosis. *Cold Spring Harbor*
2 *perspectives in medicine*. 2018; 8: a028928.
- 3 57. Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive impairment in
4 multiple sclerosis across disease subtypes. *Multiple Sclerosis Journal*. 2017; 23: 1258-67.
- 5 58. Hubbard NA, Sanchez Araujo Y, Caballero C, et al. Evaluation of visual-evoked cerebral
6 metabolic rate of oxygen as a diagnostic marker in multiple sclerosis. *Brain Sciences*. 2017; 7:
7 64.
- 8 59. Buch S, Chen Y and Haacke EM. Susceptibility mapping of the dural sinuses and other
9 superficial veins in the brain. *Magnetic resonance imaging*. 2019; 57: 19-27.
- 10 60. Wei H, Cao S, Zhang Y, et al. Learning-based single-step quantitative susceptibility
11 mapping reconstruction without brain extraction. *NeuroImage*. 2019; 202: 116064.

12

A.**B.****C.****D.**

